Holen Sie sich die Stockscreener-App
306.56
1.00%
2.18
Schlusskurs vom Vortag:
$304.38
Offen:
$304.2
24-Stunden-Volumen:
236.16K
Relative Volume:
0.30
Marktkapitalisierung:
$8.52B
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-33.43
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
-3.10%
1M Leistung:
+11.49%
6M Leistung:
+438.48%
1J Leistung:
+296.16%
1-Tages-Spanne:
$298.38
$318.00
1-Wochen-Bereich:
$298.38
$326.83
52-Wochen-Spanne:
$26.70
$326.91
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
307.32 | 8.44B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $450 - 富途资讯
Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock - Investing.com
SG Americas Securities LLC Invests $715,000 in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis speeds up R&D plans for seizure therapy after FDA feedback - MSN
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Nisa Investment Advisors LLC Has $378,000 Stake in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines stock hits 52-week high at $318.24 By Investing.com - Investing.com Nigeria
Praxis Precision Medicines (PRAX) Valuation As NDA Plans And New Clinical Leadership Point To Commercial Transition - Sahm
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 12-Month HighWhat's Next? - MarketBeat
Praxis Precision Medicines stock hits 52-week high at $318.24 - Investing.com
PRAX Stock Price, Forecast & Analysis | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - Chartmill
Behavioral Patterns of PRAX and Institutional Flows - Stock Traders Daily
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus - Insider Monkey
Praxis Precision Medicines plans two NDA submissions by mid-February - Investing.com Nigeria
Aug PreEarnings: Can Praxis Precision Medicines Inc outperform in the next rallyPortfolio Value Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Is Praxis Precision Medicines (PRAX) Price Missing The Story After A 326% One-Year Surge? - Sahm
Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom - TechStock²
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 7%Here's Why - MarketBeat
Praxis Precision Medicines (PRAX) Price Target Increased by 14.92% to 471.78 - Nasdaq
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy - PharmiWeb.com
Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge? - Yahoo Finance
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - Investing News Network
Buyout Rumor: Can Praxis Precision Medicines Inc deliver consistent dividendsJuly 2025 Trends & Smart Money Movement Alerts - baoquankhu1.vn
Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy - Quiver Quantitative
Praxis Precision Medicines Appoints Orrin Devinsky as Head of Clinical Strategy - marketscreener.com
US Biotech Share Sales Deliver Biggest First Week Since 2021 - Bloomberg.com
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 6.1%Here's Why - MarketBeat
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress - Investing News Network
Praxis Precision Medicines (PRAX) Sets Ambitious Targets for 202 - GuruFocus
PRAX: Wedbush Raises Price Target Despite "Underperform" Rating - GuruFocus
Wedbush Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Needham analyst keeps a buy rating on Praxis Precision Medicines, Inc. (PRAX) - MSN
Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX) - Yahoo Finance
20 Best Performing Stocks in 2025 - Insider Monkey
Will Praxis Precision Medicines Inc. stock see PE expansionPerformance Line Overview & quick comparison of popular models - ulpravda.ru
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biopharmaceutical company uses stock grants to attract three new employees - Stock Titan
How Praxis’s Big Equity Raise, Ulixacaltamide Breakthrough Status And Board Shake-Up At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story - Sahm
Praxis Precision (PRAX) Announces Key Leadership Changes - GuruFocus
Praxis Precision Medicines appoints new board members, promotes executives By Investing.com - Investing.com India
Praxis Precision Medicines appoints new board members, promotes executives - Investing.com
Praxis Precision Medicines Announces Key Management Appointments - TradingView — Track All Markets
Praxis Precision Medicines Announces New Board Appointments and Executive Promotions to Drive Growth and Commercial Readiness - Quiver Quantitative
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - Chartmill
Will Praxis Precision Medicines Inc. stock reach all time highs in 2025 - ulpravda.ru
How strong is Praxis Precision Medicines Inc. stock balance sheet2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - ulpravda.ru
Will Praxis Precision Medicines Inc. stock benefit from commodity pricesJuly 2025 Volume & Real-Time Market Sentiment Alerts - ulpravda.ru
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):